Back to Newsroom

Arena Pharmaceuticals Receives Additional Patent for BELVIQ® (lorcaserin HCl) from United States Patent and Trademark Office

SAN DIEGO and WOODCLIFF LAKE, N.J., April 7, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc., announced today that the US Patent and Trademark Office granted Arena US Patent No. 8,999,970, which describes a method for selecting appropriate patients based on renal function for BELVIQ® (lorcaserin HCl), a serotonin 2C receptor agonist approved for weight management.

Click here to read more